Zollino Marcella, Marangi Giuseppe, Ponzi Emanuela, Orteschi Daniela, Ricciardi Stefania, Lattante Serena, Murdolo Marina, Battaglia Domenica, Contaldo Ilaria, Mercuri Eugenio, Stefanini Maria Chiara, Caumes Roseline, Edery Patrick, Rossi Massimiliano, Piccione Maria, Corsello Giovanni, Della Monica Matteo, Scarano Francesca, Priolo Manuela, Gentile Mattia, Zampino Giuseppe, Vijzelaar Raymon, Abdulrahman Omar, Rauch Anita, Oneda Beatrice, Deardorff Matthew A, Saitta Sulagna C, Falk Marni J, Dubbs Holly, Zackai Elaine
Istituto di Genetica Medica, Università Cattolica Sacro Cuore, Roma, Italy.
Istituto di Neuropsichiatria Infantile, Università Cattolica Sacro Cuore, Roma, Italy.
J Med Genet. 2015 Dec;52(12):804-14. doi: 10.1136/jmedgenet-2015-103184. Epub 2015 Sep 30.
The 17q21.31 deletion syndrome phenotype can be caused by either chromosome deletions or point mutations in the KANSL1 gene. To date, about 60 subjects with chromosome deletion and 4 subjects with point mutation in KANSL1 have been reported. Prevalence of chromosome deletions compared with point mutations, genotype-phenotype correlations and phenotypic variability have yet to be fully clarified.
We report genotype-phenotype correlations in 27 novel subjects with 17q21.31 deletion and in 5 subjects with KANSL1 point mutation, 3 of whom were not previously reported.
The prevalence of chromosome deletion and KANSL1 mutation was 83% and 17%, respectively. All patients had similar clinical features, with the exception of macrocephaly, which was detected in 24% of patients with the deletion and 60% of those with the point mutation, and congenital heart disease, which was limited to 35% of patients with the deletion. A remarkable phenotypic variability was observed in both categories, mainly with respect to the severity of ID. Cognitive function was within normal parameters in one patient in each group. Craniosynostosis, subependymal heterotopia and optic nerve hypoplasia represent new component manifestations.
In KANSL1 haploinsufficiency syndrome, chromosome deletions are greatly prevalent compared with KANSL1 mutations. The latter are sufficient in causing the full clinical phenotype. The degree of intellectual disability (ID) appears to be milder than expected in a considerable number of subjects with either chromosome deletion or KANSL1 mutation. Striking clinical criteria for enrolling patients into KANSL1 analysis include speech delay, distinctive facial dysmorphism, macrocephaly and friendly behaviour.
17q21.31缺失综合征的表型可由KANSL1基因的染色体缺失或点突变引起。迄今为止,已报道约60例染色体缺失患者和4例KANSL1基因点突变患者。与点突变相比,染色体缺失的患病率、基因型-表型相关性及表型变异性尚未完全阐明。
我们报告了27例新发17q21.31缺失患者和5例KANSL1基因点突变患者的基因型-表型相关性,其中3例点突变患者此前未被报道。
染色体缺失和KANSL1基因突变的患病率分别为83%和17%。所有患者具有相似的临床特征,但有差异,24%的染色体缺失患者和60%的点突变患者存在巨头畸形,35%的染色体缺失患者有先天性心脏病。两类患者均观察到显著的表型变异性,主要体现在智力障碍的严重程度方面。每组各有1例患者的认知功能在正常范围内。颅缝早闭、室管膜下异位和视神经发育不全是新发现的组成性表现。
在KANSL1单倍体不足综合征中,与KANSL1基因突变相比,染色体缺失更为普遍。后者足以导致完整的临床表型。在相当数量的染色体缺失或KANSL1基因突变患者中,智力障碍程度似乎比预期的要轻。将患者纳入KANSL1分析的显著临床标准包括语言发育迟缓、独特的面部畸形、巨头畸形和友好行为。